药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
4-Bromo-2,5-dimethoxyamphetamine
Pinaverium
The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Delafloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Lurasidone
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Delafloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Solifenacin
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Delafloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Triclabendazole
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Triclabendazole.
4-Bromo-2,5-dimethoxyamphetamine
Rupatadine
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Rupatadine.
4-Bromo-2,5-dimethoxyamphetamine
Olodaterol
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Olodaterol.
4-Bromo-2,5-dimethoxyamphetamine
Acrivastine
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Delafloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Trimebutine
The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Delafloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Vilanterol
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Delafloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Ezogabine
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Delafloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Pipemidic acid.
4-Bromo-2,5-dimethoxyamphetamine
Rufloxacin
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Rufloxacin.
4-Bromo-2,5-dimethoxyamphetamine
Piromidic acid
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Piromidic acid.
4-Bromo-2,5-dimethoxyamphetamine
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Acetyldigoxin.
4-Bromo-2,5-dimethoxyamphetamine
Lorajmine
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Lorajmine.
4-Bromo-2,5-dimethoxyamphetamine
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Oxolinic acid.
4-Bromo-2,5-dimethoxyamphetamine
Prajmaline
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Prajmaline.
4-Bromo-2,5-dimethoxyamphetamine
Cibenzoline
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Cibenzoline.
4-Bromo-2,5-dimethoxyamphetamine
Pilsicainide
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Pilsicainide.
4-Bromo-2,5-dimethoxyamphetamine
Givinostat
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Givinostat.